سعر فليكسوتيد 125مكجم/ بخاخ استنشاق 2026

Flixotide Evohaler CFC-free pressurised inhaler, fluticasone propionate 125 micrograms per actuation, number of actuations not stated, by GlaxoSmithKline (imported); inhaled corticosteroid for asthma prophylaxis.

• Prophylactic management of asthma (regular preventive treatment) in adults and children over 4 years of age.Population: Adults and children over 4 yearselectronic medicines compendium (eMC)

• Very common: candidiasis of the mouth and throat (rinsing the mouth with water after use may help). Common: hoarseness or dysphonia, contusions, and pneumonia in COPD patients.International label, same formulation · electronic medicines compendium (eMC)
• Uncommon: cutaneous hypersensitivity reactions. Rare: oesophageal candidiasis. Very rare: angioedema, anaphylactic reactions, hyperglycaemia, dyspepsia and arthralgia.International label, same formulation · electronic medicines compendium (eMC)
• Frequency not known: depression, aggression, epistaxis and blurred vision.International label, same formulation · electronic medicines compendium (eMC)

• Hypersensitivity to fluticasone propionate or to any of the excipients.International label, same formulation · electronic medicines compendium (eMC)

• Not for relief of acute asthma symptoms, for which a short-acting inhaled bronchodilator is needed; increasing use of reliever medication signals worsening control and the need for review.International label, same formulation · electronic medicines compendium (eMC)
• Paradoxical bronchospasm with an immediate increase in wheezing may occur after dosing; treat at once with a fast-acting bronchodilator, stop the medicine and review therapy.International label, same formulation · electronic medicines compendium (eMC)
• Systemic effects may occur, especially at high doses for long periods: Cushing's syndrome or cushingoid features, adrenal suppression, growth retardation in children, decreased bone mineral density and psychological or behavioural effects.International label, same formulation · electronic medicines compendium (eMC)

• Ritonavir (and other strong CYP3A4 inhibitors, including cobicistat-containing products)Ritonavir can increase fluticasone propionate plasma levels several hundred-fold, causing systemic corticosteroid effects including Cushing's syndrome and adrenal suppression; avoid unless the benefit outweighs the risk.electronic medicines compendium (eMC)
• Ketoconazole and itraconazoleKetoconazole increased fluticasone propionate exposure by about 150% after a single inhaled dose; use with caution with potent CYP3A4 inhibitors such as itraconazole.electronic medicines compendium (eMC)
• ErythromycinErythromycin (a moderate CYP3A4 inhibitor) produced only a negligible increase in fluticasone propionate exposure.electronic medicines compendium (eMC)

• Use in pregnancy only if the expected benefit to the mother outweighs any possible risk to the fetus; a retrospective epidemiological study found no increased risk of major congenital malformations after first-trimester exposure.International label, same formulation · electronic medicines compendium (eMC)
• Excretion into human breast milk has not been investigated; consider use in breastfeeding only if the expected benefit to the mother outweighs any possible risk to the child.International label, same formulation · electronic medicines compendium (eMC)

• Fluticasone propionate: Glucocorticoid with potent anti-inflammatory activity in the lungs or nasal mucosa at recommended doses, with low systemic exposure (UK Flixotide/Flixonase SmPCs, section 5.1).